Trial Profile
A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate Coronavirus Disease 2019 (COVID-19)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Jan 2023
Price :
$35
*
At a glance
- Drugs Leronlimab (Primary)
- Indications COVID 2019 infections; Respiratory insufficiency
- Focus Proof of concept; Therapeutic Use
- Sponsors CytoDyn
- 02 Aug 2021 Primary endpoint (Clinical Improvement as assessed by change in total symptom score (for fever, myalgia, dyspnea and cough)) has not been met, according to a CytoDyn media release.
- 23 Sep 2020 According to a CytoDyn media release, this study has been selected for an oral presentation at the upcoming Special isirv-Antiviral Group Conference on Therapeutics for COVID-19.The Conference is sponsored by the International Society for Influenza and other Respiratory Virus Diseases, an independent and international scientific professional society promoting the prevention, detection, treatment, and control of influenza and other respiratory virus disease.
- 10 Sep 2020 According to a CytoDyn media release, the company will host an investment community conference call on Wednesday, September 16, 2020 to provide updates regarding the U.S. Food and Drug Administration (FDA) emergency IND (eIND) program.